Mouse IgG1 GOLD, Clone hksp OR Mouse IgG1 GOLD, Clone hksp84

Made in PDL2 knockout mouse fusion partner X63Ag8.653 myeloma cells

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multistep process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Functional grade preclinical antibodies may be stored sterile as received at 28°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ 70°C. Avoid Repeated Freeze Thaw Cycles.

Next Day 28°C

Clone 3.2.B8 recognizes an epitope on mouse/human PDL2 and has been shown to bind to both mouse and human PDL2 equally well

PD1 is a 5055 kD member of the B7 Ig superfamily. PD1 is also a member of the extended CD28/CTLA4 family of T cell regulators and is suspected to play a role in lymphocyte clonal selection and peripheral tolerance. The ligands of PD1 are PDL1 and PDL2, and are also members of the B7 Ig superfamily. PD1 and its ligands negatively regulate immune responses. PDL1, or B7Homolog 1, is a 40 kD type I transmembrane protein that has been reported to costimulate T cell growth and cytokine production. The interaction of PD1 with its ligand PDL1 is critical in the inhibition of T cell responses that include T cell proliferation and cytokine production. PDL1 has increased expression in several cancers. Inhibition of the interaction between PD1 and PDL1 can serve as an immune checkpoint blockade by improving Tcell responses In vitro and mediating preclinical antitumor activity. Within the field of checkpoint inhibition, combination therapy using antiPD1 in conjunction with antiCTLA4 has significant therapeutic potential for tumor treatments. PDL2 is a 25 kD type I transmembrane ligand of PD1. Via PD1, PDL2 can serve as a coinhibitor of T cell functions. Regulation of T cell responses, including enhanced T cell proliferation and cytokine production, can result from mAbs that block the PDL2 and PD1 interaction.

PDL2 is expressed on dendritic cells, liver, few transformed cell lines, and a subset of macrophages.

PD1, uncharacterized receptor

Binds to PD1 and alternative receptor;

1.) Akbari O, Stock P, Singh AK, Lombardi V, Lee WL, Freeman GJ, Sharpe AH, Umetsu DT, Dekruyff RH. PDL1 and PDL2 modulate airway inflammation and iNKTcell dependent airway hyperreactivity in opposing directions. Mucosal Immunol. 2010; 3:81 91. PMCID: PMC2845714
2.) Xiao Y, Yu S, Zhu B, Bedoret D, Bu X, Francisco LM, Hua P, DukeCohan JS, Umetsu DT, Sharpe AH, DeKruyff RH*, Freeman GJ* (* indicates cosenior authors). RGMb is a novel binding partner for PDL2 and its engagement with PDL2 promotes respiratory tolerance. J Exp Med. 2014; 211:94359. PMCID: PMC4010901.